# A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

> **NCT07662057** · PHASE1 · RECRUITING · sponsor: **Arcus Biosciences, Inc.** · enrollment: 130 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AB102
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07662057
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662057, "A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07662057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*